Celiac Disease – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Celiac Disease – Pipeline Review, H1 2017’, provides an overview of the Celiac Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Celiac Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Celiac Disease

– The report reviews pipeline therapeutics for Celiac Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Celiac Disease therapeutics and enlists all their major and minor projects

– The report assesses Celiac Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Celiac Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Celiac Disease

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Amyra Biotech AG

Calypso Biotech SA

Circle33 LLC

enGene Inc

F. Hoffmann-La Roche Ltd

Glenmark Pharmaceuticals Ltd

ImmusanT Inc

Innovate Biopharmaceuticals Inc

Intrexon Corp

Sanofi

Takeda Pharmaceutical Company Ltd

Zedira GmbH

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Celiac Disease - Overview 6

Celiac Disease - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Celiac Disease - Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Celiac Disease - Companies Involved in Therapeutics Development 23

Amgen Inc 23

Amyra Biotech AG 23

Calypso Biotech SA 24

Circle33 LLC 24

enGene Inc 25

F. Hoffmann-La Roche Ltd 25

Glenmark Pharmaceuticals Ltd 26

ImmusanT Inc 26

Innovate Biopharmaceuticals Inc 27

Intrexon Corp 27

Sanofi 28

Takeda Pharmaceutical Company Ltd 28

Zedira GmbH 29

Celiac Disease - Drug Profiles 30

AMG-714 - Drug Profile 30

AVX-176 - Drug Profile 32

Biologic for Celiac Disease - Drug Profile 33

BNZ-2 - Drug Profile 34

CALY-002 - Drug Profile 35

ERW-1041E - Drug Profile 36

GBR-830 - Drug Profile 37

Kuma-010 - Drug Profile 38

larazotide acetate - Drug Profile 39

latiglutenase - Drug Profile 42

Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Tropical Spastic Paraparesis and Oncology - Drug Profile 45

Nexvax-2 - Drug Profile 46

Nexvax-3 - Drug Profile 49

Oligonucleotides for Celiac Disease - Drug Profile 50

Protein for Celiac Disease - Drug Profile 51

Recombinant Enzymes to Inhibit Gluten for Celiac Disease - Drug Profile 52

Recombinant Protein for Celiac Disease - Drug Profile 53

RG-7625 - Drug Profile 54

Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile 55

Vaccine for Celiac Disease - Drug Profile 56

Vaccine for Celiac Disease - Drug Profile 58

vedolizumab - Drug Profile 59

ZED-1227 - Drug Profile 66

ZED-754 - Drug Profile 67

Celiac Disease - Dormant Projects 68

Celiac Disease - Product Development Milestones 69

Featured News & Press Releases 69

Appendix 79

Methodology 79

Coverage 79

Secondary Research 79

Primary Research 79

Expert Panel Validation 79

Contact Us 79

Disclaimer 80

List of Tables

List of Tables

Number of Products under Development for Celiac Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Celiac Disease – Pipeline by Amgen Inc, H1 2017

Celiac Disease – Pipeline by Amyra Biotech AG, H1 2017

Celiac Disease – Pipeline by Calypso Biotech SA, H1 2017

Celiac Disease – Pipeline by Circle33 LLC, H1 2017

Celiac Disease – Pipeline by enGene Inc, H1 2017

Celiac Disease – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Celiac Disease – Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Celiac Disease – Pipeline by ImmusanT Inc, H1 2017

Celiac Disease – Pipeline by Innovate Biopharmaceuticals Inc, H1 2017

Celiac Disease – Pipeline by Intrexon Corp, H1 2017

Celiac Disease – Pipeline by Sanofi, H1 2017

Celiac Disease – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Celiac Disease – Pipeline by Zedira GmbH, H1 2017

Celiac Disease – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Celiac Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports